TenNor Therapeutics Received Government Grant to Support Development of Dua-Action Molecules for the Treatment of MDR/XDR-TB.

TenNor Therapeutics has received a new drug innovation grant under the 12th five-year plan to support the development of dual-action molecules for the treatment of MDR/XDR-TB. As part of a consortium of academic and industry partnership led by Institute of Materia Medica of Chinese Academy of Medical Sciences, TenNor will utilize its proprietary dual-action molecular technology to advance a novel series of dual-action compounds for the treatment of drug-resistant tuberculosis. The TenNor team led by Founder and CEO Dr. Zhenkun Ma attended the project kick-off meeting in Beijing on January 25, 2016. Dr. Ma was appointed as a member of the Project Scientific Advisory Committee and gave a talk on New TB Drug Development Strategy and Pipeline. On behalf of TenNor Therapeutics, Dr. David Wan provided a project update during the meeting.

About TenNor Therapeutics

Incorporated in 2013, TenNor Therapeutics is a near-commercial stage biotechnology company dedicated to the discovery, development and commercialization of differentiated therapies to address unmet medical needs in disease areas associated with bacterial infections and bacterial metabolism. Empowered by its proprietary multi-targeting conjugate molecule technology, TenNor Therapeutics aims to deliver the best therapeutic solutions to overcome the limitations of conventional treatments and improve patient outcomes. As of January 24, 2026, TenNor Therapeutics had built a pipeline of seven innovative programs, including two Core Products, namely, rifasutenizol (TNP-2198), a new molecular entity (“NME”) drug candidate used as part of a triple therapy in combination with amoxicillin and a proton pump inhibitor for the treatment of Helicobacter pylori (“H. pylori”) infection in China and U.S. as well as monotherapy for bacterial vaginosis and C. difficile infection in China; and rifaquizinone (TNP-2092 injection), a triple-targeting antibacterial drug candidate for the treatment of implant-associated bacterial infections, i.e. acute bacterial skin and skin structure infection (“ABSSSI”) and prosthetic joint infection (“PJI”), as well as left ventricular assist device infection (“LVADI”) and catheter-related bloodstream infection (“CRBSI”) in China and the U.S.

For more information, please visit: www.tennortherapeutics.com